# Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

> **NCT06151236** · PHASE2 · RECRUITING · sponsor: **Melanoma Institute Australia** · enrollment: 20 (estimated)

## Conditions studied

- Merkel Cell Carcinoma

## Interventions

- **DRUG:** Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination

## Key facts

- **NCT ID:** NCT06151236
- **Lead sponsor:** Melanoma Institute Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-11
- **Primary completion:** 2026-12
- **Final completion:** 2034-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06151236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06151236, "Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06151236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*